This Shanxi pharmaceutical company is great! 300 million antimicrobials were the first to be evaluated.

Pharmaceutical Network July 30, recently issued a notice that the company received the Approval of the State Drug Administration issued by the phosphorus mycomycin ammonia threealcohol scattered "drug supplement application approval notice", the drug the first in the country through the consistency evaluation.
minotdata show that in 2019 China's public medical institutions terminal phosphomycin ammonia threealcohol sales of more than 300 million yuan.
phosphomycin ambutanol dispersion is suitable for acute simple urinary tract infection, asymptomatic myuurial disease and prevention of infection caused by surgery or lower urinary tract diagnosis.
the species is now included in the National Health Insurance List and the National Essential Medicines Directory. according to
-Minet. Sales of phosphomycin ammonia butthree alcohol in 2019 were more than 300 million yuan, up 10.16 percent year-on-year, in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions).
China's public medical institutions terminal phosphomycin ammonia lycol sales (units: 10,000 yuan) is currently listed in the domestic phosphomycin ammonia three-alcohol form with dispersants and particulates, phosphormyin ammonia three-particle approved enterprises only the original research manufacturer Zanbang Pharmaceuticals, phosphormycin indomidan alcohol loose manufacturers have source medicine, Northeast Pharmaceuticals, Warner Large Pharmaceutical Factory and other 3 enterprises.
2019 in China's public medical institutions terminal phosphomycin ammonia colcol manufacturers competition pattern, the source of the pharmaceutical accounted for 47.47 percent of the market share, Warner Pharmaceuticals accounted for 26.09 percent, Northeast Pharmaceuticals accounted for 25.94 percent, Zanbang Pharmaceuticals accounted for only 0.5 percent.
-meter internal network consistency evaluation database shows that the source medicine, Northeast Pharmaceuticals, Warner Pharmaceuticals have submitted phosphorin ammonia triol dispersion consistency evaluation supplement applications.
Warner Pharmaceuticals' supplementary application for the product has been issued, the approval conclusion is approval supplement, The Northeast Pharmaceutical Supplement application for the product is still under review, and the product has been successfully evaluated by Yuyuan Pharmaceuticals.
phosphomycin ammonia glycol dispersal consistency evaluation supplementary application source: Minet database, company announcement.